Havoc Awarded SBIR Phase III Contract by Army Applications Laboratory for Multi-Domain Mission Collaborative Autonomy

PROVIDENCE, R.I., Oct. 12, 2026 /PRNewswire/ -- Havoc, the collaborative autonomy software company, today announced it has been awarded a Small Business Innovation Research (SBIR) Phase III contract from the Army Applications Laboratory (AAL). The award will fund continued development of Havoc's collaborative-autonomy capabilities for logistics resupply across multiple hardware platforms.

The contract builds on Havoc's work under xTech Overwatch, where the company's technology was selected from a field of more than 40 competing vendors. Since then, Havoc's team has worked to demonstrate that its autonomy software can operate across domains, orchestrating the delivery of critical resupply to Soldiers via both air and ground platforms.

"This award does more than fund the next phase of our work with the Army," said Paul Lwin, CEO of Havoc. "The Phase III designation means any agency in the federal government, not just the Department of War, can now bring Havoc on board through a streamlined, non-competitive path, drawing on the work we've already proven out. We built this technology to solve a Department of War logistics problem, and now the door is open for it to solve similar problems anywhere in government."

Havoc credited the Army Applications Laboratory and the SBIR program with creating a pathway that moves quickly from demonstrated capability to fielded contract.

Under the new contract, Havoc will expand its multi-domain capabilities to orchestrate the delivery of critical resupply to Soldiers via air and ground platforms, in direct response to a need identified by its customer at Overwatch/Pegasus Charge, 1st Cavalry Division.

About Havoc

Havoc is a leader in all-domain collaborative autonomy. Its software-defined hardware approach powers military and commercial-grade autonomous systems across sea, air, and land to sense, decide, and act together in complex and contested environments. Havoc connects assets, enabling them to share information, adapt in real time, and continue operating even when communications are disrupted or denied. Havoc optimizes mission performance and minimizes human risk. Learn more at havocai.com.

SOURCE Havoc AI

Share this article

SAGE TECHNOLOGIES LEADS INDUSTRY IN DIGITIZATION OF MILITARY NIGHT VISION GOGGLES

Company Addresses Market Challenges and Integration of AI Applications

WASHINGTON, Oct. 12, 2026 /PRNewswire/ -- AUSA 2026 -- Sage Technologies, an innovator in low-latency digital data processing and defense electronics, announced today the release of its DPVS military-grade digital night vision goggles. DPVS is designed to address the Department of War's (DOW) current requirements around soldier-borne digital vision and soldier connectivity. Leveraging expertise gained from the IVAS program, the new product leads the industry in quality of low-light performance, matching current analog NVG systems in the market today. Unlike analog systems, Sage's digital version allows for the benefits of advanced technology, including real-time command and control data sharing as well as the integration of AI.

Utilizing commercially available components and the Army's MOSA strategy (Modular Open Systems Approach), Sage's night vision technology is designed to deliver real-time situational awareness for military personnel, civil agencies, and first responders.

"Our mission at Sage Technologies has always been to solve complex, real-world problems on the front line leveraging the latest technologies available," said Steve Cantrell, CEO and President of Sage Technologies. "By fusing advanced digital sensors with real-time data processing, this system provides operators with situational awareness in the modern connected battlefield."

Building on Sage's legacy as a trusted supplier to the DOW for over 30 years, the DPVS goggles integrate low-light sensors and real-time computing to ensure 24/7 operational capability where traditional analog night vision systems fall short.

Key features of the new digital night vision platform include:

- Advanced Sensor Integration: Offers the best low-light visible (LLVis) sensor on the market for high-resolution optical imaging in degraded visual environments.

- Ability to integrate AI: Enables state-of-the-art image enhancement software onboard the platform.

- Ultra-Low Latency Processing: Leverages Sage's proprietary embedded processing to provide ultra-fast digital data processing, eliminating display lag for high-tempo operations.

- Tactical Network Compatibility: Integrates seamlessly with tactical Android systems (such as ATAK) to display real-world situational awareness data directly to the operator's display.

- Helmet-Mounted Design: Engineered specifically for dynamic tactical environments, with a fit for all common helmets.

For more information about Sage Technologies leading advanced digital solutions visit www.gosage.com.

About Sage Technologies

Sage Technologies is a design, engineering, and manufacturing firm specializing in advanced electronics, embedded FPGA systems, and vision sensor integration. For over three decades, Sage has served as a primary developer of integrated vision and situational awareness solutions for the U.S. Department of War, civil agencies, and commercial industries around the globe.

Media Contacts:

Hope Rhoads

SmartMark Communications for Sage Technologies

Email: [email protected]

Phone: 817-696-5295

Website: smartmarkglobal.com

Ofir Shavit

Sage Technologies

Email: [email protected]

Phone: (215) 658-0500 ext. 205

Website: www.gosage.com

SOURCE Sage Technologies

Share this article

Former CFTC Senior Counsel Danielle Abada joins Mayer Brown

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Mayer Brown today announced that Danielle Abada has joined the firm's Capital Markets practice as a partner in the New York office. She joins the firm from the U.S. Commodity Futures Trading Commission (CFTC), where she served as Senior Special Counsel in the Market Participants Division and previously served as Senior Counsel to CFTC Commissioner Kristin N. Johnson.

"We're pleased to welcome Danielle to our firm," said firm Chair Jon Van Gorp. "Her experience at the CFTC will benefit clients as they navigate a rapidly evolving derivatives and digital assets regulatory environment that has seen significant innovation and market growth."

At the CFTC, Danielle advised on complex legal, regulatory, and policy matters affecting CFTC-regulated entities and advanced the Commission's priorities on regulatory and market developments, including crypto assets and blockchain technologies, prediction markets and event contracts, and artificial intelligence.

Prior to her government service, in private practice, Danielle represented financial institutions and fintechs on a broad range of regulatory, compliance, transactional, and legislative matters. She also advised clients on the use of emerging and evolving technologies, including distributed ledgers, digital assets, and artificial intelligence. Danielle has represented banks, swap dealers, broker-dealers, exchanges, asset and investment managers, hedge funds and proprietary trading firms in a range of banking, derivatives and securities regulatory and transactional matters.

Danielle joins lawyers in the firm's preeminent Derivatives & Structured Products and Fintech practices. Mayer Brown has been named "Americas Law Firm of the Year (Overall)" at GlobalCapital's Americas Derivatives Awards for five consecutive years, including most recently in 2026. The firm is ranked in Tier 1 by Chambers USA, IFLR1000 and The Legal 500 US in various derivatives and structured products categories. The firm is also ranked in Tier 1 by The Legal 500 US for Fintech and ranked as a leading firm by Chambers FinTech in five FinTech Legal categories for the United States, including Corporate, Securities, and Financing.

Mayer Brown is a leading international law firm positioned to represent the world's major corporations, funds, and financial institutions in their most important and complex transactions and disputes.

Please visit mayerbrown.com for comprehensive contact information for all our offices.

Mayer Brown is a global legal services provider comprising associated legal practices that are separate entities, including Mayer Brown LLP (Illinois, USA), Mayer Brown International LLP (England & Wales), Mayer Brown Hong Kong LLP (a Hong Kong limited liability partnership) and Tauil & Chequer Advogados (a Brazilian law partnership) (collectively, the "Mayer Brown Practices"). The Mayer Brown Practices are established in various jurisdictions and may be a legal person or a partnership. PK Wong & Nair LLC ("PKWN") is the constituent Singapore law practice of our licensed joint law venture in Singapore, Mayer Brown PK Wong & Nair Pte. Ltd. More information about the individual Mayer Brown Practices and PKWN can be found in the Legal Notices section of our website.

"Mayer Brown" and the Mayer Brown logo are the trademarks of Mayer Brown.

© 2026 Mayer Brown. All rights reserved.

Attorney Advertising. Prior results do not guarantee a similar outcome.

SOURCE Mayer Brown

Share this article

Beverly Wilshire, Beverly Hills, A Four Seasons Hotel Named #1 Hotel in All of Los Angeles in the 2026 Conde Nast Traveler's Readers' Choice Awards

BEVERLY HILLS, Calif., Oct 12, 2026 /PRNewswire/ -- Out of over 1,000 hotels in the Los Angeles area, Beverly Wilshire, Beverly Hills, A Four Seasons Hotel is elated to announce it has been recognized as the #1 Hotel in Los Angeles in the 2026 Conde Nast Traveler's Readers' Choice Award.

Condé Nast Traveler received more than 798,867 survey responses from readers in the United States, rating their travel experiences across the globe, to offer a comprehensive look at the places they eagerly anticipate revisiting. The Readers' Choice Awards, with its unparalleled legacy as the travel industry's longest-running and most prestigious accolades from their readers, remains the ultimate symbol and acknowledgment of excellence within the travel sector.

"As Regional Vice President and General Manager of this legendary property, it brings me great pride to know that our guests experience the same excellence and hospitality that I am fortunate to witness every day from our team," says Reed Kandalaft, Regional Vice President and General Manager. "I am extremely proud of this recognition as it is a direct result of their warmth, genuine care and the memorable experiences they provide our guests."

Beverly Wilshire, Beverly Hills, A Four Seasons Hotel has been the preferred address for celebrities, royalty and the international elite since opening in 1928. Nearing its centennial, the hotel proudly stands at the intersection of Wilshire Boulevard and Rodeo Drive, placing guests nearby to designer shopping, fine dining and postcard-worthy views. Experience unparalleled luxury at Beverly Wilshire, Beverly Hills, A Four Seasons Hotel.

About Beverly Wilshire, Beverly Hills, A Four Seasons Hotel

Since opening in 1928, Beverly Wilshire, Beverly Hills, A Four Seasons Hotel has been an icon of Hollywood glamour where cinematic history and modern luxury converge. Standing at the intersection of luxury and fashion, it is the only landmark property to anchor the Golden Triangle, offering guests unrivalled proximity, service and access - the quintessential Beverly Hills experience. The hotel features 395 refreshed accommodations as well as a Michelin-recommended steak restaurant CUT by Wolfgang Puck, all-day dining at THE Blvd Restaurant with views of Rodeo Drive, a Forbes Five-Star Spa, and outdoor Mediterranean-style pool modeled after Sophia Loren's Italian villa pool.

Press Contact

Kiersten Dunn

310-385-3917

[email protected] 

SOURCE Four Seasons Hotels and Resorts

Share this article

Recognising an individual who has made a lasting contribution to the branded residences industry.

LONDON, Oct. 12, 2026 /PRNewswire/ -- Chris Graham, founder of London-based real estate consultancy Graham Associates, has been named Industry Icon at the inaugural Global Branded Residence Awards.

This prestigious award recognises an individual who has made a lasting contribution to the branded residences industry, whose work has helped to shape the sector, influence its development, and raise industry standards.

Decided by public vote, Graham's Industry Icon win reflects the reputation he has built over two decades working in luxury real estate and his contribution to the overall growth of the branded residences sector. A regular industry commentator and speaker, he is author of two of the industry's leading reports, 'Branded Residences: An Overview' and 'The Branded Residences Compendium''.

The panel selected four other finalists from a comprehensive list of nominations, including Sonia Cheng, CEO of Rosewood Hotel Group, John Hitchcox, founder of YOO, Dean Main, founder of Rhodium, and Kevin Wash at VOS Business Consultants.

The awards ceremony was hosted online by Boutique Hotel News editor Eloise Hanson alongside Piers Brown, CEO of International Hospitality Media.

www.globalbrandedresidenceawards.com

About Chris Graham

Chris Graham is managing director of Graham Associates, a London-based real estate marketing consultancy he founded in 2008. He has spent more than two decades working with luxury residential and mixed-use real estate developers around the world, building an impressive portfolio of landmark projects. A frequent industry commentator and international speaker, he is author of the industry's leading reports in the secor, Branded Residences: An Overview (now in its 6th edition) and TheBranded Residences Compendium, a comprehensive listing of over 250 brands active in the market. www.gagms.com

About the Global Branded Residence Awards 2026

Almost 200 entries from around the world were submitted for the Global Branded Residence Awards 2026, recognising achievements across a broad range of categories spanning regional markets, design, technology, sales and marketing, industry contribution, and the World's Best Branded Residence. The judging panel included leading voices in branded residences, luxury hospitality, real estate, investment, brand strategy, communications, and experience design from across the globe. It was chaired by Eloise Hanson, editor of Boutique Hotel News, the awards organiser.

SOURCE Graham Associates

Share this article

Best Accounts Payable Software for Small Business (2026): Melio Named Top Solution for Flexible Vendor Payments by Software Experts

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Software Experts has recognized Melio as the top solution for flexible vendor payments, making it one of the best accounts payable software for small businesses. The review examined how the platform handles invoice capture, payment approvals, vendor transactions, accounting synchronization, and cash flow management.

Best Accounts Payable Software for Small Business

- Melio - an accounts payable software platform designed to help U.S. businesses capture bills, route approvals, pay domestic and international vendors, and synchronize payment records with supported accounting systems.

The recognition reflects Melio's ability to connect the main stages of accounts payable within an approachable platform. Businesses can capture invoices, establish approval controls, schedule payments, and record completed transactions without relying on separate spreadsheets, banking portals, and manual reconciliation.

AP Automation Reduces Manual Payment Work

Accounts payable automation replaces repetitive invoice entry, approval follow-ups, and payment recording with a connected digital workflow. The process gives businesses clearer visibility into due dates, approvers, vendors, and transaction status from the moment an invoice arrives through final payment.

Melio uses optical character recognition to capture information from uploaded invoices. Bills can also be sent to a dedicated inbox. Vendor details, line items, amounts, and due dates are entered automatically for review. Authorized users can check the information and make corrections before approving payment.

This process may reduce errors associated with manual entry, including duplicate payments, incorrect amounts, and missed due dates. Digital records also create a clearer audit trail and provide a more current view of outstanding obligations.

Automation may become more valuable as invoice volume increases. A connected AP system allows an existing finance team to process more bills without adding another manual workflow. Melio reports that customers save more than 15 hours per month on average, based on internal data, company records, and user surveys.

Flexible Payment Options Support Different Vendor Requirements

Vendor payment preferences are rarely consistent. One supplier may accept ACH, another may request a check, and an overseas contractor may require payment in a local currency. Melio brings these options into one platform while separating how a business funds a transaction from how the vendor receives the money.

Available payment methods include ACH bank transfers, credit and debit cards, wire transfers, and paper checks. Faster options include same-day bank transfers, instant transfers, fast checks, overnight checks, and same-day wires. Fees vary according to the funding method and delivery speed.

Card-funded payments may help a business manage the timing of cash leaving a bank account. Card use may also earn rewards, depending on the card program. However, Melio lists a standard 2.9% fee for card-funded domestic payments, subject to the receiving method and other terms. Potential rewards or payment timing benefits should be considered alongside transaction fees and possible card interest.

International payments can be sent in U.S. dollars or supported local currencies. Melio states that payments can be delivered to eligible vendors in more than 80 countries. This provides a centralized option for businesses working with overseas suppliers, contractors, and freelancers.

Bill Capture, Approvals, and Accounting Sync Work Together

Every disconnected step creates another opportunity for an invoice to be delayed, entered twice, or recorded incorrectly. A connected AP workflow reduces those handoffs by keeping invoice capture, approval history, payment status, and accounting records within the same process.

Custom approval workflows can be based on vendor, payment amount, employee role, or other business rules. Multi-level approvals allow higher-value or sensitive transactions to receive added review. Team members can be assigned specific permissions, helping businesses separate viewing, approval, and administrative responsibilities.

Approved bills can be paid individually, scheduled in advance, set as recurring payments, or processed in batches. Melio's mobile application also allows authorized users to review, approve, decline, and send payments away from a desktop computer.

Contractor management tools support W-9 collection and taxpayer information validation. Melio can connect with Tax1099 for 1099 e-filing, although a separate Tax1099 account and related fees may apply.

The platform also includes Agent Mel, an AI assistant designed to answer questions about bills, vendors, and payments. The feature supports routine information requests, while the main workflow keeps payment records connected to the corresponding invoice and approval history.

Pricing and Integrations Depend on the Selected Plan

Subscription price is only one part of the cost of accounts payable software. Payment volume, accounting integrations, user access, delivery speed, and transaction methods can all affect the appropriate plan. Melio offers several tiers designed around those different operational requirements.

Melio's five plans scale with transaction volume and integration needs rather than bundling features evenly across tiers.

Go, the free plan, supports one user and includes five free ACH payments per month, AI bill capture, a dedicated bills inbox, international payments, and the option to pay by card, wire, or check.

Core runs $25 per month and raises the free ACH allowance to 20. It adds QuickBooks Online and Xero synchronization, batch payments, custom approval workflows, W-9 collection, and 1099 automation, making it a fit for small businesses that need accounting sync and more structured AP controls.

Boost, at $55 per month, extends the ACH allowance to 50 and introduces advanced user roles, QuickBooks Desktop synchronization, and premium phone support. Unlimited, at $80 per month, removes ACH and seat limits entirely and adds NetSuite synchronization. Annual billing lowers the monthly cost on paid tiers, and a custom-priced Platinum plan is available for high-volume businesses.

Once a plan's included ACH payments are used, additional ACH transactions cost $0.50 each. Card payments, checks, wires, expedited delivery, and international payments carry separate fees depending on the plan.

Melio is built for U.S. small and midsize businesses that want AP automation without the overhead of an enterprise system. Its bill capture, approval controls, flexible vendor payment options, and tiered accounting integrations were cited in Melio's recognition from Software Experts.

For the full review, visit Software Experts.

About Melio

Melio serves US SMBs and accounting firms with accounts payable, receivable and cash flow management solutions. Headquartered in New York with offices in Tel Aviv, Israel. Founded in 2018, Melio has scaled rapidly to serve over 80,000 customers. Melio's leading platform integrates with and maintains partnerships with financial institutions, allowing businesses to sync payments data and avoid manual entry. Melio also acts as a technology service provider for vertical SaaS platforms and financial institutions including Capital One and Shopify, and distribution partners including Fiserv through a syndication model. This enables Melio to potentially reach millions of small businesses to provide embedded accounts payable products.

About Software Experts: Software Experts delivers in-depth news on the digital tools shaping today's consumer experience. As an affiliate, Software Experts may earn commissions from sales generated using links provided.

SOURCE SoftwareExperts.org

Share this article

First ground-up Life Time in Tampa-Sarasota features resort-style beach club, 14 pickleball courts and everything designed for fitness, recovery and connection

Key Highlights:

- Location: 5000 Lakewood Ranch Blvd. N., Sarasota, FL 34240

- Scale: The destination spans more than 180,000 square feet.

- 86,000-square-foot club

- Nearly 50,000-square-foot beach club

- Nearly 50,000-square-foot pickleball retreat

- Expansive Fitness Floor: State-of-the-art cardio and strength-based equipment, open space for functional training and dynamic personal training.

- Resort-style Beach Club: A leisure pool with waterslides, five-lane lap pool, cabanas, lounge chairs and an outdoor dining area and pool-side service.

- 14 pickleball courts: Three indoor and 11 outdoor.

- Something for everyone: Rejuvenation suites featuring cold plunge, whirlpool, steam and sauna; a full-service LifeSpa and salon; signature training including Alpha, GTX and the new CTR reformer class; LifeCafe; Kids Academy; and coworking spaces.

- Click Here for Photos and Video of Lakewood Ranch

CHANHASSEN, Minn. and LAKEWOOD RANCH, Fla., Oct. 12, 2026 /PRNewswire/ -- Life Time (NYSE: LTH), the nation's premier healthy lifestyle brand, today opened its Lakewood Ranch Athletic Country Club, a new wellness and social destination created for one of the nation's fastest-growing communities. Life Time's first ground-up athletic country club in the Tampa-Sarasota region spans more than 180,000 square feet and features a resort-style Beach Club, 14 pickleball courts, dynamic training and recovery experiences, and spaces for members to dine, work, relax and connect.

The opening marks Life Time's second location on Florida's Gulf Coast and eighth in the state. Designed as a true extension of members' daily lives, Life Time Lakewood Ranch brings fitness, wellness, recreation, recovery and social connection together in one, resort-inspired setting for people of all ages.

"Lakewood Ranch is a community that values active, healthy living, making it a natural fit for Life Time," said Parham Javaheri, Executive Vice President, President of Club Operations and Chief Property Development Officer at Life Time. "This is truly a wellness and social destination, blending the energy of an athletic country club with the ease and escape of a resort. It's a place where members can train, recover, relax, play and connect with family and friends while living healthy, happy lives."

Additional Highlights include:

- Dedicated Studios and Spaces for signature group training programs and exclusive fitness classes including GTX, Alpha, Ultra Fit and in-demand CTR (Core Tone Reform) athletic reformer workout, along with mind body programming and Pilates studio

- Cardio, Strength and Recovery Zones with best-in-class equipment, Hydro- and full body massage chairs, compression and vibration therapy tools.

- Full-service LifeSpa offering body, skin, hair and nail services.

- LifeCafe + bar/lounge with a nutrition-focused dine-in and social gathering areas.

- Life Time Work Club Lounge with complimentary coworking space for members.

- Kids Academy with programming and supervised care for kids 3 months to 11 years old.

- Rejuvenation suites with sauna, steam, whirlpool, and cold plunge in luxury dressing rooms.

- LifeClinic offering licensed chiropractors.

Life Time Lakewood Ranch joins seven other athletic country clubs across Florida, including Harbour Island in Tampa, Winter Park in Orlando, Coral Gable and Miami at The Falls in Miami, East and West Boca Raton and Palm Beach Gardens. Life Time Jacksonville will debut in 2027 with additional locations throughout the state to come.

The new destination strengthens Life Time's Gulf Coast presence while bringing the company's integrated approach to healthy living, healthy aging and social connection to one of the state's most desirable and fastest-growing communities.

Members also gain access to Life Time's broader healthy way of life ecosystem, including the complimentary Life Time app featuring L•AI•C™, expert coaching, digital wellness content and the company's portfolio of athletic events.

Life Time Lakewood Ranch is located at 5000 Lakewood Ranch Blvd N, Sarasota, FL 34240. For more information, visit the club website, call 941-870-1250 or follow along on the club's Instagram.

For more information about Life Time, visit LifeTime.life, explore the Life Time Newsroom or follow LinkedIn, Facebook and Instagram, or download the complimentary Life Time App.

Frequently Asked Questions:

What is Life Time Lakewood Ranch? 

Life Time Lakewood Ranch is a more than 180,000-square-foot athletic country club located in Lakewood Ranch. It offers a resort-style Beach Club, expansive fitness floor, boutique studios, pickleball, recovery and spa amenities, LifeCafe dining, a complimentary work lounge and kids programming.

When does Life Time Lakewood Ranch open? 

Life Time Lakewood Ranch opens at 6a.m. on October 12, 2026.

Where is Life Time Lakewood Ranch located? What's the contact info? 

Life Time Lakewood Ranch is located at 5000 Lakewood Ranch Blvd N, Sarasota, FL 34240. The club can be reached at 941-870-1250. Membership and additional information are available on the Life Time Lakewood Ranch website.

What amenities and classes does Life Time Lakewood Ranch offer? 

Life Time Lakewood Ranch features a resort-style Beach Club with a leisure pool, waterslides and botha five-lane  and six-lane lap pool; three indoor and 11 outdoor pickleball courts; and an LT Recovery Zone with HydroMassage, CryoLounge chairs, Normatec compression and Hyperice therapy. Group fitness spans barre, cycle, Pilates, strength and yoga, along with Life Time signature formats including Alpha, GTX, MB360 and the new CTR (Core, Tone, Reform) athletic reformer class. The club also includes a full-service LifeSpa, LifeCafe dining and a Kids Academy for children ages three months to 11 years.

How do I become a member of Life Time Lakewood Ranch?

Membership information is available at the Life Time Lakewood Ranch club website or by calling 941-870-1250.

About Life Time

Life Time (NYSE: LTH) empowers people to live healthy, happy lives through its more than 195 athletic country clubs across the U.S. and Canada, the complimentary and comprehensive Life Time app featuring its L•AI•C™ AI-powered health companion, and more than 30 iconic athletic events. Serving people ages 90 days to 90+ years, the Life Time ecosystem uniquely delivers healthy living, healthy aging, and healthy entertainment experiences, a range of unique healthy way of life programs, highly trusted LTH nutritional supplements and more. Recognized as a Great Place to Work®, the company is committed to upholding an exceptional culture for its nearly 50,000 team members.

SOURCE Life Time, Inc.

Share this article

Awards from IBEX, the Sea Tow Foundation and Soundings Trade Only 

recognize Garmin products and companywide innovation

OLATHE, Kan., Oct. 12, 2026 /PRNewswire/ -- Garmin (NYSE: GRMN) today announced it was the proud recipient of several awards recognizing product innovation, boating safety and technology leadership at the 2026 International BoatBuilders' Exhibition and Conference (IBEX) tradeshow. Garmin Signal™ VHF 400 received an IBEX Innovation Award; Garmin OnBoard™ earned a National Boating Safety Award from the Sea Tow Foundation; and Garmin was awarded a Soundings Trade Only EPIC Award for Development & Technology. Garmin was also ranked No. 4 on the program's Top 10 Most EPIC Companies list, the marine industry's only award program that recognizes the work of the entire company, rather than a single product or individual.

"These honors reflect the many ways Garmin is working to improve the boating experience, from strengthening communication and safety on the water to developing new technologies that move the industry forward. We're proud to see both our products and our broader approach to innovation recognized by so many respected organizations across the marine industry." 

–Susan Lyman, Garmin Vice President of Consumer Sales and Marketing  

IBEX Innovation Award 

Garmin Signal VHF 400 won the OEM Electronics category after standing out among 100 product entries. It combines VHF, DSC and a Class B SOTDMA AIS transponder on a color touchscreen in a compact unit designed to fit nearly any helm. Judges also highlighted its NMEA 2000 integration, support for 12V and 24V systems, and separately powered fist mic with magnetic mounting, which makes the radio easier to install on a wide range of boats. The IBEX Innovation Awards program is managed by the National Marine Manufacturers Association and judged by Boating Writers International (BWI).

National Boating Safety Award 

The Garmin OnBoard System received the Sea Tow Foundation's Best Boating Safety Product or Technology Innovation Award, recognizing for-profit companies helped to advance boating safety in the recreational boating industry. The wireless man-overboard (MOB) detection and engine cutoff system can monitor up to eight tags, alert those aboard when an MOB event is detected and stop the engine if the captain falls overboard. The honor marks Garmin's sixth consecutive Boating Safety Award. 

Soundings Trade Only EPIC Awards 

For the ninth consecutive year – since the award program's inception – Garmin was named a Top 5 company by Soundings Trade Only, a leading trade publication for the recreational boating industry. EPIC – an acronym for exceptional, purposeful, innovative and compassionate – honors companies that are transforming the marine industry through advancements in technology, innovative products and processes, workforce initiatives and more. Garmin also won the Development & Technology category and was commended for pushing the marine industry forward through innovation evidenced by an impressive 15 product launches during the eligibility period.

To learn more about Garmin's award-winning suite of marine electronics, visit garmin.com/marine.

Engineered on the inside for life on the outside, Garmin products have revolutionized life for anglers, sailors, mariners and boat enthusiasts everywhere. Committed to developing the most innovative, highest quality, and easiest to use marine electronics the industry has ever known, Garmin believes every day is an opportunity to innovate and a chance to beat yesterday. For the 12th consecutive year, Garmin was named the Manufacturer of the Year by the National Marine Electronics Association (NMEA). For more information, visit Garmin's virtual Newsroom, email our press team, connect with @garminmarine on social media, or follow our blog.

About Garmin International, Inc. Garmin International, Inc. is a subsidiary of Garmin Ltd. (NYSE: GRMN). Garmin Ltd. is incorporated in Switzerland, and its principal subsidiaries are located in the United States, Taiwan and the United Kingdom. Garmin is a registered trademarks, and Signal and OnBoard are trademarks of Garmin Ltd. or its subsidiaries. All other brands, product names, company names, trademarks and service marks are the properties of their respective owners. All rights reserved.

Notice on Forward-Looking Statements: 

This release includes forward-looking statements regarding Garmin Ltd. and its business. Such statements are based on management's current expectations. The forward-looking events and circumstances discussed in this release may not occur and actual results could differ materially as a result of known and unknown risk factors and uncertainties affecting Garmin, including, but not limited to, the risk factors listed in the Annual Report on Form 10-K for the year ended December 27, 2025, filed by Garmin with the Securities and Exchange Commission (Commission file number 0-31983). Copies of such Form 10-K and Form 10-Q are available at https://www.garmin.com/en-US/investors/sec/. No forward-looking statement can be guaranteed. Forward-looking statements speak only as of the date on which they are made and Garmin undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

MEDIA CONTACT: 

Carly Hysell

913-397-8200

[email protected] 

SOURCE Garmin International, Inc.

Share this article

Patients report positive changes across all measured areas of daily living

SEOUL, South Korea, Oct. 12, 2026 /PRNewswire/ -- After showing meaningful improvements in both the movement and daily lives of people with Parkinson's disease, and new drug will be submitted for regulatory approval.

Patients with Parkinson's, who can have difficulty moving, reported improvements in measures of daily living from the potential treatment, which also restored their 'good' movement time for an average of 36 more minutes a day than using their regular medication alone. Following these promising ARISE clinical trial results, which were presented at the International Congress of Parkinson's Disease and Movement Disorders, the drug, solengepras, will now be submitted to the Federal Drug Administration (FDA) in the United States for approval.

"It is especially encouraging that in addition to the improvements in the good 'on' time, the patients themselves felt overall benefits in their usual motor function," said Ron Postuma, Chair of the MDS International Congress Scientific Program Committee. "In fact, the self-reported improvements are higher than you might expect for a 36-minute on time difference, which shows there is still more to explore about the possibilities of this drug."

Solengepras works differently than other drugs currently on the market, so its progress could also open the door for further innovations using similar techniques.

Drooling and saliva was the most significant self-reported change, and other outcomes included improved daytime sleepiness.

About the 2026 MDS International Congress of Parkinson's Disease and Movement Disorders®:

The MDS International Congress is the premier annual event to advance the clinical and scientific discipline of Movement Disorders, including Parkinson's disease. Convening thousands of leading clinicians, scientists and other health professionals from around the globe, the International Congress will introduce more than 2,000 scientific abstracts and provide a forum for education and collaboration on latest research and treatment findings.

About the International Parkinson and Movement Disorder Society:

The International Parkinson and Movement Disorder Society® (MDS), an international society of more than 12,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about MDS, visit www.movementdisorders.org.

SOURCE International Parkinson and Movement Disorder Society

Share this article

T-MAXIMUM's B7-H3-Targeted Allogeneic CAR-T MT027 Receives FDA Clearance for Phase 2 Study in Brain Metastases from Lung and Breast Cancer

BEIJING, Oct. 12, 2026 /PRNewswire/ -- T-MAXIMUM PHARMACEUTICAL ("T-MAXIMUM") today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate a Phase 2 clinical study of MT027, its internally developed, B7-H3-targeted universal (allogeneic) CAR-T therapy, for the treatment of patients with brain metastases from lung cancer and breast cancer.

This is the second Phase 2 study of MT027 to receive FDA clearance. MT027 was previously cleared by the FDA to proceed with a Phase 2 study in recurrent glioblastoma, and has been granted Orphan Drug Designation (ODD) and Fast Track Designation (FTD). With two FDA-cleared Phase 2 programs, T-MAXIMUM has established a dual-indication portfolio for universal CAR-T therapy covering both primary and metastatic intracranial solid tumors.

Brain Metastases: An Unanswered Clinical Question Despite Advances in Systemic Therapy

Brain metastases commonly arise in patients with lung cancer, breast cancer, melanoma, renal cell carcinoma, and colorectal cancer. International studies estimate that approximately 20% of cancer patients may develop brain metastases over the course of their disease, a proportion that can reach 20% to 40% among patients with advanced solid tumors.[1][2] For patients, this means far more than an additional lesion on imaging: brain metastases may be accompanied by headaches, seizures, and cognitive and motor impairment, directly affecting daily life and subsequent treatment options.

This is a truly global clinical challenge. In 2022, there were nearly 20 million new cancer cases worldwide, including nearly 2.5 million new cases of lung cancer and approximately 2.3 million new cases of female breast cancer – the two leading primary tumor types giving rise to brain metastases.[3] Asia accounts for roughly half of all new cancer cases globally;[4] in the United States, an estimated 200,000 to 300,000 patients are newly diagnosed with brain metastases each year.[2] This large patient population means brain metastasis is not a niche need, but a question that oncology worldwide must continue to answer.

Systemic therapies can help control disease throughout the body, but treatment of intracranial lesions often remains constrained by multiple factors, including the blood-brain barrier, tumor heterogeneity, and the need to preserve neurological function. This is especially true for patients who experience intracranial progression after prior therapy, for whom there remains a need for more treatment options that are validated intracranially while balancing safety and accessibility.

Consecutive Clinical Milestones Built on Long-Term Product and Translational Groundwork

MT027's recent series of regulatory milestones is no coincidence. It reflects an integrated capability across product, manufacturing, clinical development, and regulatory affairs built around intracranial solid tumors – one that is now advancing from early exploration toward more systematic clinical validation.

First, a foundation of clinical data. The company has accumulated sustained clinical experience in local delivery, repeat dosing, and safety monitoring for intracranial solid tumors. Years of clinical experience and data with MT027 have already led to two FDA-cleared Phase 2 programs. Data from an investigator-initiated trial (IIT) of MT026, a program built on the same platform, were published in Nature Communications in 2026: among 5 patients with recurrent high-grade glioma, 1 complete response and 3 partial responses were observed, for an objective response rate (ORR) of 80%, with no treatment-related Grade 3 or higher adverse events.

Early clinical data for MT027 in patients with refractory brain metastases from lung cancer were previously presented at the IASLC 2026 World Conference on Lung Cancer (WCLC 2026). Five heavily pretreated patients with no guideline-recommended subsequent treatment options completed treatment; among the 3 evaluable patients, 2 partial responses were observed. The safety profile was favorable, with no Grade 3 or higher adverse events and no graft-versus-host disease (GvHD). These rigorous exploratory clinical studies provide an important basis for the clinical translation of allogeneic, locally delivered CAR-T therapy in intracranial solid tumors.

Second, a well-defined manufacturing process. MT027 is manufactured using a fully non-viral gene-editing process – a generational departure from the industry's mainstream lentiviral vector approach – offering potential advantages in product safety, batch-to-batch consistency, and cost control. The manufacturing process was established and locked prior to entering Phase 2 clinical development.

Third, leadership measured not only by getting there first, but by advancing systematically. For an innovative cell therapy company, leadership in regulatory progress comes from coordinated advancement across product, manufacturing, clinical development, and regulatory strategy. MT027's consecutive entry into FDA-cleared Phase 2 clinical development demonstrates T-MAXIMUM's ability to translate its prior groundwork into a repeatable and scalable clinical development capability.

Management Commentary

"Receiving FDA clearance for two consecutive Phase 2 studies of MT027 marks a pivotal step built on our sustained work in intracranial solid tumors. From glioma to brain metastases, we have always let the data speak and put clinical value first. Going forward, we will continue to rigorously evaluate the product's safety and potential clinical value through well-designed clinical studies, steadily advancing product supply, clinical execution, and the generation of key data, as we explore new possibilities for patients who lack effective treatment options."

About MT027

MT027 is an investigational, B7-H3-targeted universal (allogeneic) CAR-T cell therapy developed by T-MAXIMUM using a fully non-viral gene-editing process and administered via local intracranial delivery. MT027 has received FDA Orphan Drug Designation and Fast Track Designation and is being evaluated in FDA-cleared Phase 2 studies in recurrent glioblastoma and in brain metastases from lung cancer and breast cancer.

About T-MAXIMUM PHARMACEUTICAL

T-MAXIMUM PHARMACEUTICAL is a clinical-stage cell therapy company focused on developing universal (allogeneic) CAR-T therapies for intracranial solid tumors with high unmet medical need, including recurrent glioblastoma and brain metastases. Through engineered cell therapies, local delivery strategies, and clinical translation capabilities, the Company is advancing more accessible treatment approaches with the potential to support repeat dosing. Its lead program, MT027, is a B7-H3-targeted universal CAR-T therapy that has received FDA clearance to initiate Phase 2 clinical studies in recurrent glioblastoma and brain metastases. MT027 has also received Orphan Drug Designation (ODD) in high-grade glioma and Fast Track Designation (FTD) for recurrent or progressive glioblastoma. T-MAXIMUM is working to translate its accumulated capabilities in product development, manufacturing, and clinical execution into continued innovation across both primary and metastatic intracranial solid tumors, with the goal of creating new possibilities for patients with limited treatment options.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the clinical development, potential therapeutic benefits, manufacturing advantages, and regulatory progress of MT027 and other product candidates. These statements are based on current expectations and are subject to risks and uncertainties, including those inherent in clinical development, regulatory review, and manufacturing, that could cause actual results to differ materially. Early clinical results from small numbers of patients may not be predictive of results in larger studies. MT027 is an investigational product, and its safety and efficacy have not been established. T-MAXIMUM undertakes no obligation to update any forward-looking statement, except as required by law.

References

SOURCE T-MAXIMUM PHARMACEUTICAL

Share this article